However, the “PSA pathway” is criticized for its weak sensitivity and specificity for clinically significant PCa diagnosis, which may result in over-diagnosis, and therefore overtreatment, of clinically insignificant PCa [2, 3]. Here, KLK3 is linked to posterior cortical atrophy.